Latest Headlines

Latest Headlines

Astellas, Medivation to amp up unbranded Xtandi marketing for pre-chemo use

Astellas and Medivation haven't been marketing Xtandi much for the pre-chemotherapy indication in prostate cancer it won last fall. Begun two months ago, the direct-to-consumer efforts--mostly in print--has appeared in journals such as  Patient Resourc e; it also includes some direct relationship marketing.

Medivation buys into PD-1, picking up where Teva left off

The prostate cancer experts at Medivation are getting into the hot field of checkpoint inhibitors for cancer, agreeing to pay Israel's CureTech as much as $335 million for the full rights to a promising Phase II asset.

Pre-chemo nod for Medivation's Xtandi sets up showdown with J&J's Zytiga

Johnson & Johnson's next-gen prostate cancer pill, Zytiga, has been cruising since it hit the market back in April 2011, but now, it may be vulnerable to market share losses for the first time. The FDA has approved Medivation and Astellas' rival, Xtandi, for use in prostate cancer patients before chemo, giving the pill a head-to-head shot at J&J's blockbuster.

Medivation, Astellas ask FDA to approve Xtandi for pre-chemo prostate cancer use

Astellas and Medivation today said they are asking the FDA for approval for Xtandi to be used on patients with metastatic castration-resistant prostate cancer who have not received chemotherapy.

Astellas, Medivation's cancer drug Xtandi scores new upbeat PhIII results

Medivation and Astellas Pharma unveiled final results on primary and secondary efficacy endpoints from their Phase III PREVAIL trial of Xtandi (enzalutamide), showing that the drug delayed tumor growth and prolonged the lives of patients with metastatic prostate cancer who previously have not undergone chemotherapy.

Prostate-cancer prodigy Xtandi shines as pre-chemo treatment

Xtandi has reached a key milestone: success in a Phase III trial eyeing the drug from Medivation and Astellas as a prechemo treatment for advanced prostate cancer.

Cramer vs. Cramer: What's the next big biotech takeover target?

Now that the final wrap-up of Amgen's $10.4 billion buyout of Onyx is under way, analysts can get back to one of their favorite pastimes: Speculating on the next big biotech M&A deal that could make executives rich and investors' portfolios burst with big gains.

Jazz CFO joins Medivation's board of directors

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it...

Zytiga, Xtandi will help pump prostate cancer market to $9.1B

The market for prostate cancer drugs is expected to double by 2021 to $9.1 billion, thanks in part to the debut of new, more expensive drugs. According to Decision Resources, Johnson & Johnson's ($JNJ) Zytiga, along with Medivation ($MDVN) and Astellas Pharma's new Xtandi, will help drive sales growth in 7 major drug markets.

Promising prostate cancer data triggers $50M venture haul for Aragon

Just days after reporting positive interim results from a mid-stage study of its closely-watched prostate cancer drug, San Diego-based Aragon Pharmaceuticals has topped up its bank account with a whopping $50 million venture round--bringing its total haul this year alone to $88 million.